ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863

Its studies are mostly in Stomach Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Jun 16, 20231 company-led study, 1 open or runningNext primary completion: Mar 16, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Jun 16, 2023Jun 16, 2023Mar 16, 2029phase 2 · NCT06005493
  • Named in AstraZeneca’s own pipeline as AZD5863, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2023First study: phase 2 study in Stomach NeoplasmsFirst studyNCT06005493 · 392 planned · United States, China, France and more
  2. Sep 25, 2026Primary completion moved from 2027-07-16 to 2029-03-16Date moved laterphase 2 · +20 months · NCT06005493

Ahead

  1. Mar 16, 2029Primary completion: phase 2 study in Stomach NeoplasmsNCT06005493

TargetBeta

“An affinity-optimized T-cell engaging (TCE) and human bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administrat…”NCIt, read by Claude

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
emaretamigruleAstellas Pharmaphase 33

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06005493Stomach Neoplasms · United States, China, France and more2RecruitingMar 16, 2029392

How it is read

Names in the registry

  • “AZD5863”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.